| mRNA |
Dasatinib |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
3e-05 |
| mRNA |
17-AAG |
CCLE |
pan-cancer |
AAC |
0.21 |
0.0002 |
| mRNA |
S-Trityl-L-cysteine |
FIMM |
pan-cancer |
AAC |
-0.73 |
0.0009 |
| mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.001 |
| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
0.001 |
| mRNA |
navitoclax:pluripotin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.002 |
| mRNA |
lapatinib |
CCLE |
pan-cancer |
AAC |
0.17 |
0.002 |
| mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.002 |
| mRNA |
TGX221 |
GDSC1000 |
pan-cancer |
AAC |
-0.17 |
0.002 |
| mRNA |
nakiterpiosin |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.002 |